← All companies

BCRX — BIOCRYST PHARMACEUTICALS INC

Materials · Biological Products, (No Diagnostic Substances) · Nasdaq

CIK 0000882796 · FYE 1231 · All Form 4 filings on EDGAR ↗

5Insiders filing

5Transactions

+$49kReported buys

−$0Reported sells

0Cluster events

Window in data: 2026-08-31 → 2026-08-31 · Data as of 2026-09-03

Insiders

Insider	Role	Txns	Reported value
Frank Steven	Director	1	$12k
Milne Jill C.	Director	1	$12k
MILANO VINCENT	Director	1	$11k
McKee Amy E	Director	1	$6k
Stonehouse Jon P	Director	1	$6k

Transaction history

Filing date	Trade date	Ticker	Insider	Type	Shares	Price	Value	Cluster
2026-09-02	2026-08-31	BCRX	Stonehouse Jon P Director	A routine	644	$9.70	+$6k	—
2026-09-02	2026-08-31	BCRX	Milne Jill C. Director	A routine	1,288	$9.70	+$12k	—
2026-09-02	2026-08-31	BCRX	MILANO VINCENT Director	A routine	1,159	$9.70	+$11k	—
2026-09-02	2026-08-31	BCRX	McKee Amy E Director	A routine	644	$9.70	+$6k	—
2026-09-02	2026-08-31	BCRX	Frank Steven Director	A routine	1,288	$9.70	+$12k	—

Known data limitations

Form 4 lag: insiders have 2 business days to file after a trade (weekends and holidays extend this), and this site re-ingests once daily — a transaction can appear here roughly three business days after it happened.
13F lag: quarterly 13F-HR holdings cover the prior quarter-end and are due 45 days after it — every institutional position shown here is at least 45 days old by construction, often more.
CUSIP→ticker gaps: 13F positions are reported by CUSIP; some holdings cannot be matched to a current ticker (delistings, corporate actions, thin metadata) and appear without one or are omitted from ticker-level views.
EDGAR timing variability: institutions file at different hours and days within their windows; amended filings (4/A, 13F-HR/A) can restate earlier periods, so historical aggregates may change between batches.

Insider Atlas is a descriptive research site, not investment advice — see the methodology for the full provenance chain.